Madeleine Ngo Baleba, Cameroon

Centre Mère et Enfant laboratory

Author Of 2 Presentations

DISTRIBUTION OF STREPTOCOCCUS PNEUMONIAE SEROTYPES AFTER THE INTRODUCTION OF PCV 13 IN CAMEROON (ID 266)

Abstract

Background

In July 2011, the 13- valent pneumococcal conjugate vaccine (PCV 13) was introduced into the routine immunization program in Cameroon.After the introduction of this vaccine, post-vaccine surveillance continued to monitor vaccine effectiveness and detect the emergence of new strains

We describe the pneumococcal serotypes that circulated after the introduction of PCV 13.

Methods

Retrospective review data from sentinel laboratory-based surveillance system from 2011 to 2018. Lumbar puncture was performed on children under five years admitted with suspected meningitis at the paediatric hospital in Yaoundé. Cerebrospinal fluid (CSF) specimens were tested by Gram stain, culture, latex agglutination and/ or Polymerase Chain Reaction (PCR). Serotyping/grouping, and/or whole genome sequencing were performed on Streptococcus pneumoniae isolates

Results

Among 8108 CSF specimens tested, 116 cases of meningitis were confirmed .89(76.7%) were positive for Streptococcus pneumoniae. PCR serotyping identified 19(39.5%) and 29(60.4%) S. pneumoniae PCV13 and non-PCV13 serotypes respectively. The most frequent non vaccine pneumococcal serotype was serotype 2 (13.7%) and the most frequent vaccine pneumococcal serotypes were 6A/ 6B (26%)

Conclusions

PCV 13 serotypes still remain in circulation . There is need for continuous surveillance and monitoring how vaccines can affect the evolution of strains over a long period of time

Hide

CHANGES IN ANTIMICROBIAL SUSCEPTIBILITY OF STREPTOCOCCUS PNEUMONIAE AMONG CHILDREN UNDER-FIVE YEARS ADMITTED WITH BACTERIAL MENINGITIS IN YAOUNDÉ AFTER PNEUMOCOCCAL CONJUGATE VACCINE INTRODUCTION IN CAMEROON. (ID 291)